Gamida Cell

Gamida Cell is a Massachusetts-based biotechnology company that develops and commercializes cell therapeutics for the treatment of blood cancer.

Business Model:

Revenue: $0

Employees: 51-200

Detailed Gamida Cell Information

Geographic Data

Gamida Cell headquarters map

Address: 673 Boylston Street

City: Boston

State: MA

Zip: 02116

Country: US

Financial Info

Stage:

post ipo debt

Raised Last:

$75M

Raised Total:

$268M

Metrics

4,306,979Website Global Rank

2,419Website Monthly Traffic

Twitter Followers

Description

Gamida Cell is a Massachusetts-based biotechnology company that develops and commercializes cell therapeutics for the treatment of blood cancer.

Contact Phone:
+16178929080

Contact Email:

Gamida Cell went public on 10/25/2018 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
10/25/2018

IPO Valuation:
$165M

Ticker Symbol:
GMDA

IPO Price:
$8/share

Amount Raised:
$50M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
7/2017 Grant 1 $3.5M Israel Innovation Authority
Israel Innovation Authority
Israel Innovation Authority
Israel Innovation Authority
8/2005 Series C 1 $3.7M Auriga Partners
Auriga Partners
1/2014 Venture Round $4M
5/2012 Series E $0 Clal Biotechnology Industries
Teva Pharmaceutical Industries
Israel Healthcare Ventures
Denali Ventures
Auriga Partners
Amgen Ventures
Clal Biotechnology Industries
Teva Pharmaceutical Industries
Israel Healthcare Ventures
Denali Ventures
Auriga Partners
Amgen Ventures
10/2018 IPO $50M
5/2020 Post-IPO Equity $60M
9/2022 Post-IPO Debt $25M Highbridge Capital
3/2017 Equity $30M Clal Biotechnology Industries Ltd
Elbit Medical Technologies Ltd.
Novartis
10/2001 Series B 1 $9.7M Auriga Partners
Auriga Partners
6/2017 Series F $0 Israel Biotech Fund
Novartis
Clal Biotechnology Industries
Shavit Capital
Israel Healthcare Ventures
VMS Asset Management
Shavit Capital
Israel Biotech Fund
Novartis
Clal Biotechnology Industries
Shavit Capital
Israel Healthcare Ventures
VMS Asset Management
Shavit Capital
9/2022 Post-IPO Debt $25M Highbridge Capital Management
Highbridge Capital Management
9/2006 Series D $0 Israel Healthcare Ventures
Teva Pharmaceutical Industries
Elscint Biomedical Investment
Denali Ventures
Biomedical Investments
Israel Healthcare Ventures
Teva Pharmaceutical Industries
Elscint Biomedical Investment
Denali Ventures
Biomedical Investments
7/2019 Post-IPO Equity $35M
5/2000 Series A 1 $6.4M Auriga Partners
Auriga Partners
5/2016 Grant 1 $4.4M Israel Innovation Authority
Israel Innovation Authority
2/2021 Debt 1 $75M Highbridge Capital Management
Highbridge Capital Management
Highbridge Capital Management
Highbridge Capital Management
6/2017 Equity 6 $40M Shavit Capital
Israel Biotech Fund
Novartis
Clal Biotechnology Industries
Israel Healthcare Ventures
Israel Biotech Fund
Novartis
Clal Biotechnology Industries
Shavit Capital
Israel Healthcare Ventures
VMS Asset Management
Shavit Capital
5/2012 Series E 6 $10M Clal Biotechnology Industries
Clal Biotechnology Industries
9/2006 Series D 5 $16M Israel Healthcare Ventures
Israel Healthcare Ventures
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research